Hospital neglect contributed to boy's sepsis death
Medical neglect contributed to the death of a three-year-old boy who developed a strep A infection and later died of sepsis in hospital, an inquest jury has found.
Oscar Neillings had been unwell days before he was rushed to the Chesterfield Royal Hospital in Derbyshire in November 2023 but he was not given antibiotics he needed until more than two hours after being admitted.
The inquest heard his care at the hospital was "fragmented" with his sepsis missed and his parents saying they were not told how ill their son was.
Hospital bosses said they accepted the findings of the inquest.
Speaking after the verdict, Oscar's mother Stephanie Neillings said: "I am so grateful that the jury were able to see clearly what happened... the hospital left Oscar to die."
The jury reached a narrative conclusion and said Oscar died from natural causes contributed to by neglect.
Jurors were instructed to record Oscar died from sepsis following bronchopneumonia and invasive strep A infection.
Assistant coroner for Derby and Derbyshire Julie Mitchell said she would not be issuing a Prevention of Future Deaths report as she was "satisfied changes have been implemented to improve patient safety" at the hospital.
The inquest previously heard from Oscar's mother who criticised medics who treated her son in hospital and "thought she was being crazy" when she suggested he had sepsis.
Jurors heard strep A infection was not considered when Oscar attended two out-of-hours GPs appointments on 5 and 7 November.
Instead his parents were told he had a "viral upper respiratory infection" and "did not consider he would deteriorate", the coroner said.
After his condition worsened he was seen again at his family GP surgery the next morning where he had a nebuliser put on him and was taken to hospital under blue lights.
Oscar was seen by clinicians who found he had low oxygen levels and a poor respiratory rate.
He had a chest X-ray, which showed "significant right-sided consolidation" and was given intravenous fluid and steroids.
Mrs Neillings told the court doctors spoke about a chest infection and they were going to administer antibiotics but said care was "unorganised".
"I had absolutely no idea how poorly he was until right at the end," she said.
Oscar arrived at the hospital at 10:30 GMT but was not given antibiotics until 12:54 due to "delays" from a "prescribing error", the inquest heard.
Mrs Neillings said a matron came to check on Oscar later in the day and said he had deteriorated and paged for a doctor just before 15:00 and he was taken into intensive care.
Oscar went into cardiac arrest three times and died just before 17:30.
The Derbyshire Times reported consultant paediatrician Dr Nelly Ninis of London's St Mary's Hospital told the jury sepsis was "not recognised" in Oscar by staff at Chesterfield Royal Hospital, adding no-one really "owned" Oscar's care – which she described as "fragmented".
The court was told how there was evidence Oscar was in septic shock the morning of his transfer to hospital, the newspaper said.
Dr Ninis said under National Institute for Clinical Excellence sepsis protocols, a high dose of antibiotics and "rapid infusions of fluid" were needed within the first hour to reverse septic shock, it added.
The jury heard Oscar did not receive antibiotics after nearly two and a half hours in hospital and only 10ml of fluid – when he required at least 60ml, the Derbyshire Times said.
Speaking to the media on the steps of Chesterfield Coroner's Court following the verdict, Mrs Neillings said: "Our darling little boy was taken away from us and he can't come back.
"We long for our life to be how it was but have to adapt to this new normal, carry on and carry Oscar with us.
"I don't want him to be known for how he died, I want Oscar to be known for how he lived, his short life was so full of energy, happiness and love and we will be forever grateful for Oscar."
Helen Reynolds, medical negligence lawyer at Fletchers Solicitors who represented the family during the inquest, said they were now pursuing a civil claim against Chesterfield Royal Hospital NHS Foundation Trust.
She added the trust said it had produced an action plan but had not made it public.
"This inquest has brought painful clarity to what went so tragically wrong in Oscar's case," she said.
"The failings in his care are deeply distressing but the family's courage in sharing their story must lead to action.
"Any changes must be accompanied by clear deadlines, measurable outcomes, and complete transparency.
"Families deserve assurance that these commitments are being honoured and no other child will be failed in the same way."
Krishna Kallianpur, executive chief nurse at the trust, said: "At the heart of this is a family who have lost their three-year-old son and for that we offer our sincere condolences.
"We have submitted a full learning review and acknowledge the findings of HM The Coroner with the conclusion of natural causes contributed to by neglect.
"We will continue to embed the actions taken to date to ensure that we continue to learn and improve."
Follow BBC Derby on Facebook, on X, or on Instagram. Send your story ideas to eastmidsnews@bbc.co.uk or via WhatsApp on 0808 100 2210.
Boy did not get antibiotics soon enough - inquest

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
Alvotech Meets Investors and Presents at the Jefferies Global Healthcare Conference 2025 in New York, NY
REYKJAVIK, Iceland, June 02, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Jefferies Global Healthcare Conference 2025, which will be held in New York, New York June 3-5, 2025. Members of the management team will host one-on-one meetings at the conference. Dr. Balaji Prasad, Chief Strategy Officer will deliver a presentation with recent business updates at the conference on Thursday June 5, 2025, at 10:30 am-11:00 am EDT (14:30-15:00 GMT / 16:30-17:00 CET). A live video webcast of the presentation will be available to the general public and can be accessed at After the event, a recording will be available for replay for 90 days. About AlvotechAlvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech has launched two biosimilars. The current development pipeline includes biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech's commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Dr. Reddy's (EEA, UK and US), Biogaran (FR), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit Please visit our investor portal, and our website or follow us on social media on LinkedIn, Facebook, Instagram, and YouTube. ALVOTECH INVESTOR RELATIONS AND GLOBAL COMMUNICATIONS Benedikt Stefansson, in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Washington Post
7 hours ago
- Washington Post
Poop at work. It's good for you!
Well+Being Poop at work. It's good for you! June 6, 2025 | 2:52 PM GMT Gastroenterologist Dr. Trisha Pasricha has some tips for whether to poop on company time (yes), whether to wait (no) and how to relax while on the job.
Yahoo
7 hours ago
- Yahoo
Alvotech Meets Investors and Presents at the Goldman Sachs Global Healthcare Conference in Miami
REYKJAVIK, Iceland, June 06, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Goldman Sachs 46th Global Healthcare Conference, which will be held in Miami, Florida June 9-11, 2025. Members of the management team will host one-on-one meetings at the conference. Dr. Balaji Prasad, Chief Strategy Officer, will participate in a fireside chat on Wednesday June 11, 2025, at 8:00 am EDT (12:00 GMT / 14:00 CEST). A live webcast of the fireside chat will be available to the general public and can be accessed at After the event, a recording will be available for replay for 90 days. About AlvotechAlvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech has launched two biosimilars. The current development pipeline includes biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech's commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Dr. Reddy's (EEA, UK and US), Biogaran (FR), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit Please visit our investor portal, and our website or follow us on social media on LinkedIn, Facebook, Instagram, and YouTube. ALVOTECH INVESTOR RELATIONS AND GLOBAL COMMUNICATIONS Benedikt Stefansson,